Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 20/20 | 0.78 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.78 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.78 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20696517 | 0.89 | AKR1B1 (0.62) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL20696627 | 0.88 | AKR1B1 (0.78) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL29353641 | 0.87 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8505122 | 0.87 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL49012 | 0.87 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8129027 | 0.87 | AKR1B1 (0.98) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL8129830 | 0.86 | AKR1B1 (0.83) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL20696628 | 0.83 | AKR1B1 (0.67) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL8201334 | 0.83 | AKR1B1 (0.78) | AKR1B1AKR1B10AKR1A1GLO1 | |
| Zopolrestat SCHEMBL7185596 | 0.83 | AKR1B1 (0.90) | AKR1B1AKR1B10AKR1A1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238288-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | BARCLAYS BANK PLC (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20230346782-A1 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | BARCLAYS BANK PLC (GB) | 2023-11-02 | — | — | US | disclosed |
| US-20230121312-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | Applied Therapeutics, Inc. | 2023-04-20 | — | — | US | disclosed |
| US-11590131-B2 | Compositions and methods for treating galactosemia | Applied Therapeutics, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2021071965-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF PHOSPHOMANNOMUTASE 2 DEFICIENCY | APPLIED THERAPEUTICS INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20200230139-A1 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | BARCLAYS BANK PLC (GB) | 2020-07-23 | — | — | US | disclosed |
| US-20200131203-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | APPLIED THERAPEUTICS INC (US) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590131-B2 | Compositions and methods for treating galactosemia | GLA, ALDOA, GALC | AKR1B1 42/4885AKR1B10 159/4885AKR1A1 74/4885 |
| US-20200230139-A1 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | GLA, ALDOA, GALC | AKR1B1 42/4885AKR1B10 159/4885AKR1A1 74/4885 |
| US-20240238288-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | SORD, SDHA, SDHB | AKR1B1 9/4885AKR1B10 27/4885AKR1A1 14/4885 |
| US-20230121312-A1 | ALDOSE REDUCTASE INHIBITORS FOR TREATING SORBITOL DEHYDROGENASE DEFICIENCY | SORD, SDHA, SDHB | AKR1B1 9/4885AKR1B10 27/4885AKR1A1 14/4885 |
| US-20200131203-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885AKR1B10 10/4885AKR1A1 8/4885 |
| US-20230346782-A1 | COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA | GLA, ALDOA, GALC | AKR1B1 42/4885AKR1B10 159/4885AKR1A1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.